Since the initial description of a large focus of zoonotic *Plasmodium knowlesi* human cases in Sarawak, Malaysia, in 2004 \[[@CIT0001]\], knowlesi malaria has been reported from countries across Southeast Asia \[[@CIT0002], [@CIT0003]\]. In Malaysia, *P. knowlesi* now accounts for \>90% of all government-notified malaria cases \[[@CIT0004]\], with \>9500 reported cases from 2012 to 2016 \[[@CIT0004], [@CIT0005]\]. *Plasmodium knowlesi* is also increasingly reported in areas of western Indonesia \[[@CIT0009], [@CIT0010]\]. Difficulties with microscopic diagnosis \[[@CIT0002], [@CIT0011]\] have limited accurate reporting of the true incidence of knowlesi malaria, with the disease burden likely underestimated \[[@CIT0002], [@CIT0005], [@CIT0012]\]. Despite great progress in reducing human-only malaria species in many countries \[[@CIT0004], [@CIT0005]\], increasing numbers of *P. knowlesi* cases in Southeast Asia threaten regional malaria elimination. Conventional public health measures are unable to target zoonotic transmission to humans from the *P. knowlesi* reservoir in monkey hosts, particularly outdoors in agricultural or forest areas \[[@CIT0013]\].

Prospective studies have described the clinical spectrum of naturally acquired adult knowlesi malaria \[[@CIT0017], [@CIT0018]\]. Severe knowlesi malaria has been reported in adults in Southeast Asia and in adult travelers returning from these regions \[[@CIT0002], [@CIT0012], [@CIT0018], [@CIT0019]\], with the risk of severe disease at least as high as from *Plasmodium falciparum* \[[@CIT0018]\]. Deaths from knowlesi malaria have been more common in older adults and have been associated primarily with respiratory distress, hypotension, and acute kidney injury (AKI) \[[@CIT0006], [@CIT0012], [@CIT0019]\].

Malaria notification data in knowlesi-endemic areas show a median age of 31 years, much higher than that seen with *P. falciparum* and *Plasmodium vivax* \[[@CIT0007]\], although 6% (79/1325) of all notified knowlesi malaria cases in Sabah in 2014 occurred in children aged \<15 years \[[@CIT0006]\]. With the marked reduction in cases of falciparum and vivax malaria, *P. knowlesi* now accounts for around 49% of all reported pediatric malaria cases in Sabah \[[@CIT0006]\]. Despite this, there are limited descriptions of knowlesi malaria in children \[[@CIT0002], [@CIT0022]\], or comparisons between zoonotic knowlesi malaria and locally acquired malaria from the human-only species *P. falciparum* and *P. vivax* in district settings.

In this study, we compared the predefined clinical spectrum between children and adults with malaria due to *P. knowlesi* or other *Plasmodium* species infection, and evaluated predictors of disease severity in a coendemic primary care setting.

METHODS {#s5}
=======

Study Sites and Referral System {#s6}
-------------------------------

This study was conducted in Kudat Division, northwest Sabah, Malaysia, covering an area of 4623 km^2^ and with a total growth-rate adjusted Malaysian census--estimated population in 2016 of 199600 people. Each of the 3 districts in this division has a central referral hospital and subdistrict health clinics, consistent with other districts in Sabah. Malaysian Ministry of Health guidelines stipulate that all patients with fever receive microscopic blood slide screening for malaria parasites, with mandatory hospital admission, free treatment, and notification of positive cases \[[@CIT0023]\].

Subjects {#s7}
--------

Patients of all ages presenting to study hospitals with microscopy-diagnosed malaria were enrolled following written informed consent. Children were predefined as age ≤12 years, consistent with Malaysian Ministry of Health pediatric ward admission. Patients were not included in the final analysis if they were pregnant or had *Plasmodium malariae* infection on polymerase chain reaction (PCR), if *Plasmodium* species PCR was not confirmed, or if cross-check research microscopy was negative. A subset of patients with uncomplicated *P. knowlesi* and *P. vivax* malaria was also enrolled in previously reported randomized controlled treatment trials \[[@CIT0023]\].

Study Procedures {#s8}
----------------

Baseline and longitudinal clinical, laboratory, and epidemiological data were entered using standardized case record forms. Venous blood was taken for baseline investigations and then daily for microscopy and hematology during hospital admission and at the follow-up visit 28 days after treatment initiation. Severe malaria was defined using World Health Organization (WHO) 2014 research criteria \[[@CIT0026]\], including for *P. knowlesi*: hyperparasitemia threshold of 100000/μL, and jaundice defined as bilirubin \>50 μmol/L with parasite count \>20000/μL and/or creatinine \>132 μmol/L \[[@CIT0018]\]. Nonsevere anemia was defined using WHO age- and sex-based hemoglobin criteria \[[@CIT0027]\]. AKI was evaluated using Kidney Disease Outcomes Quality Working Group (KDIGO) criteria \[[@CIT0028]\]. Chronic disease was defined as hypertension; diabetes mellitus; ischemic heart disease; hyperlipidemia; or chronic kidney, liver, or respiratory disease.

Laboratory Procedures {#s9}
---------------------

Microscopic asexual parasite and gametocyte counts were calculated by research microscopists using thick blood smears and quantitated leukocyte count. Standard hospital automated hematology, biochemistry, and microbiology laboratory results were used. Final *Plasmodium* species confirmation was done using PCR \[[@CIT0029], [@CIT0030]\].

Statistical Analysis {#s10}
--------------------

We compared between-group differences with analysis of variance or Kruskal-Wallis testing for continuous variables, and Student *t* test or the Wilcoxon--Mann-Whitney test for 2-group comparisons according to distribution. For categorical variables, χ^2^ or Fisher's exact test was used. Logistic regression models were fitted to determine a priori predictors of severe malaria based on standard clinical and laboratory WHO 2014 research criteria \[[@CIT0026]\] evaluable at time of acute patient presentation to district hospital settings, including testing for model interactions and collinearity. Receiver operating characteristic (ROC) analysis was used to assess their sensitivity and specificity. Multivariate analysis controlled for age and log~e~ parasitemia; patients with hyperparasitemia as a sole severity criterion were considered nonsevere.

Ethical Considerations {#s11}
----------------------

This study was approved by the medical research ethics committees of the Ministry of Health, Malaysia; London School of Hygiene and Tropical Medicine, United Kingdom; and Menzies School of Health Research, Australia.

RESULTS {#s12}
=======

Demographics {#s13}
------------

From October 2012 until April 2016, 811 malaria patients were enrolled ([Figure 1](#F1){ref-type="fig"}). There were 481 *P. knowlesi*, 172 *P. vivax*, and 96 *P. falciparum* malaria cases included in the final analysis. From 2014 to 2015, the estimated minimum yearly malaria incidence in Kudat Division (district hospital presentations with clinical disease) for *P. knowlesi*, *P. vivax*, and *P. falciparum* was 0.79, 0.40, and 0.19 cases per 1000 people per year, respectively. Patients with knowlesi malaria had a median age of 33 years (interquartile range \[IQR\], 21--49 years), higher than those with vivax (15 years \[IQR, 9--30 years\]) and falciparum (16 years \[IQR, 10--31 years\]) malaria (*P* \< .001; [Figure 2](#F2){ref-type="fig"}). Patients aged \>50 years comprised 107 (22%) of knowlesi malaria cases, compared to 10 (6%) and 14 (15%) for falciparum and vivax malaria, respectively (*P* \< .001). A bimodal age distribution was seen for females with both *P. knowlesi* and *P. falciparum* infection. Of *P. knowlesi* cases, 44 (9%) were children, compared to 71 (41%) of *P. vivax* cases and 31 (32%) of those with *P. falciparum* malaria ([Table 1](#T1){ref-type="table"}; *P* \< .001). Only 6 (1.3%) knowlesi cases were \<5 years of age, with only 1 infant (\<1 year), a 6-week-old with no travel history or forest or plantation exposure. Compared to children with *P. knowlesi* malaria, adults were more likely to be male (79% vs 57%; *P* = .001), with this relationship also evident for *P. vivax* cases (75% vs 48%; *P* \< .001).

###### 

Baseline Demographic, Clinical, and Laboratory Features of Children

  Patient Characteristic                                   *Plasmodium knowlesi*   *Plasmodium vivax*   *Plasmodium falciparum*   *P* Value
  -------------------------------------------------------- ----------------------- -------------------- ------------------------- ------------
  Children (age ≤12 y), No. (% total)                      44 (9.1)                71 (41.3)            31 (32.3)                 \<.001
  Age, y                                                                                                                          
   Median (IQR)                                            8 (5--10)               9 (5--10)            7 (3--10)                 .095
   Range                                                   0.1--12                 0.67--12             1--12                     
  Male sex, No. (%)                                        25 (56.8)               34 (47.9)            21 (67.7)                 .170
  Previous malaria (self-reported), No. (%)                4 (9.1)                 11 (15.5)            3 (9.7)                   .526
  History of chronic disease, No. (%)                      2 (4.5)                 0                    0                         .095
  Days of fever                                            5 (3--7)                5 (3--7)             4 (3--5)                  .751
  Symptoms on enrollment, No. (%)                                                                                                 
   Rigors                                                  29 (65.9)               55 (77.5)            14 (45.2)                 **.006**
   Headache                                                34 (77.3)               55 (77.5)            21 (67.7)                 .542
   Vomiting                                                14 (31.8)               37 (52.1)            11 (35.5)                 .068
   Abdominal pain                                          19 (43.2)               9 (12.7)             9 (29.0)                  **.001**
   Diarrhea                                                4 (9.1)                 2 (2.8)              4 (12.9)                  .140
   Cough                                                   15 (34.1)               25 (35.2)            12 (38.7)                 .914
   Shortness of breath                                     3 (6.8)                 4 (5.6)              4 (12.9)                  .431
   Myalgia                                                 11 (25.0)               15 (21.1)            7 (22.6)                  .890
   Arthralgia                                              12 (27.3)               15 (21.1)            7 (22.6)                  .746
  Examination findings on enrollment                                                                                              
   Temperature, °C                                         37.1 (36.8--37.9)       37.4 (36.8--37.8)    37.1 (36.8--38)           .647
   Fever (≥37.5°C), No. (%)                                17 (38.6)               33 (46.5)            12 (38.7)                 .634
   Systolic blood pressure, mm Hg                          101 (94--109)           102 (96--110)        106 (98--112)             .356
   Heart rate, beats/min                                   104 (93--119)           105 (94--118)        117 (96--134)             .688
   Respiratory rate, breaths/min                           24 (22--27)             24 (22--28)          26 (24--28)               .081
   Oxygen saturation, %                                    99 (99--100)            99 (98--100)         100 (99--100)             .504
   Palpable liver, No. (%)                                 14 (31.8)               20 (28.2)            8 (25.8)                  .842
   Palpable spleen, No. (%)                                9 (20.5)                12 (16.9)            2 (6.5)                   .244
   Rash, No. (%)                                           1 (2.3)                 0 (0)                1 (3.2)                   .360
  Parasite count/μL                                        1722 (386--4830)        5967 (1829--13901)   7392 (1462--36546)        **\<.001**
  Parasite count/μL, range                                 36--74365               109--140500          61--635415                
  Schizont proportion, mean % (SD)                         3 (7.5)                 1 (4.0)              0 (0)                     **.013**
  Schizont proportion \>10%, No. (%)                       3 (6.8)                 1 (1.5)              0 (0)                     .138
  Parasite count \>20000/μL, No. (%)                       4 (9)                   8 (11)               12 (39)                   **.001**
  Gametocytes present, no./No. (%)                         4/35 (11)               21/66 (32)           1/11 (9)                  **.035**
  Hemoglobin, g/dL                                         10.6 (9.7--11.3)        10.1 (9.3--11.2)     10.3 (9.2--11.6)          .726
  Anemia^a^ (baseline), No. (%)                            36 (82)                 56 (79)              21 (68)                   .328
  G6PD deficiency present, no./No. (%)                     1/38 (2.6)              3/69 (4.3)           1/18 (5.6)                .852
  White blood cell count, × 10^3^/μL                       6.1 (5.1--7.5)          7.1 (5.1--8.6)       9.2 (6.4--12.7)           **.002**
  Neutrophil count, × 10^3^/μL                             2.7 (2.0--3.5)          3.3 (2.5--4.8)       3.8 (2.5--6.8)            **.015**
  Lymphocyte count, × 10^3^/μL                             2.0 (1.4--2.7)          2.2 (1.6--2.9)       2.8 (1.7--5.0)            **.025**
  Monocyte count, × 10^3^/μL                               1.1 (0.8--1.4)          0.9 (0.6--1.3)       1.2 (0.7--1.4)            .241
  Platelet count, × 10^3^/μL                               106 (80--163)           120 (93--179)        159 (83--282)             .078
  Platelet nadir, × 10^3^/μL                               78 (60--134)            104 (70--154)        129 (63--275)             **\<.001**
  Platelet nadir, d                                        1 (0--1)                1 (0--1)             1 (0--1)                  1.000
  Thrombocytopenia (platelets \<150 × 10^3^/μL), No. (%)   30 (68)                 46 (65)              13 (42)                   **.047**
  Creatinine, μmol/L                                       48 (36--57)             48 (34--58)          40 (31--53)               .267
  Urea, mmol/L                                             3.8 (2.8--4.5)          3.5 (3.0--4.6)       3.2 (2.3--4.5)            .167
  Sodium, mmol/L                                           137 (135--139)          137 (136--139)       136 (133--139)            .640
  Bilirubin, μmol/L                                        11.5 (8.3--15.8)        9.8 (6.0--14.6)      11.0 (6.8--19.7)          .474
  Glucose, mmol/L                                          5.8 (5.1--6.8)          5.7 (5.0--6.4)       6.2 (5.6--6.6)            .802
  Albumin, g/dL                                            35 (31--37)             34 (28--36)          32 (29--37)               .644
  AST, IU/L                                                25 (23--34)             24 (15--28)          37 (24--42)               .268
  ALT, IU/L                                                16 (11--32)             17 (11--28)          24 (14--32)               .270
  Bicarbonate, mmol/L                                      23 (21--25)             22 (20--26)          25 (21--26)               .418
  Acute kidney injury, No. (%)                             11 (26)                 7 (10)               10 (32)                   **.016**
  Blood culture positive^b^, No. (%)                       0/33 (0)                0/28 (0)             0/15 (0)                  1.000

Data are presented as median (IQR) unless otherwise indicated. Results are from time of enrollment unless otherwise specified.

P values in bold font indicate a value \<0.05.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range; SD, standard deviation.

^a^Anemia based on World Health Organization 2011 hemoglobin measurement criteria \[[@CIT0027]\]: age 6--59 months (≤100 g/dL), 5--11 years (\<115 g/dL), 12--14 years (\<120 g/dL), nonpregnant women ≥15 years (\<120 g/dL), pregnant women (\<110 g/dL), men ≥15 years (\<130 g/dL).

^b^Excluding results positive for skin contaminants.

![Enrollment flowchart. Abbreviations: PCR, polymerase chain reaction; *Pf*, *Plasmodium falciparum*; *Pk*, *Plasmodium knowlesi*; *Pv*, *Plasmodium vivax*.](ciy06501){#F1}

Baseline Features: Children {#s14}
---------------------------

Abdominal pain was more common in children with knowlesi compared to vivax malaria (43% vs 13%; odds ratio \[OR\], 5.2 \[95% confidence interval {CI}, 2.1--13.1\]; *P* \< .001), although vomiting occurred more often in those with *P. vivax* (*P* = .033) ([Table 1](#T1){ref-type="table"}). Children with knowlesi malaria had lower parasite counts than those with *P. vivax* (median, 1722 vs 5967 parasites/μL; *P* \< .001) and *P. falciparum* (median, 1722 vs 7392 parasites/μL; *P* \< .001). The highest parasite count recorded for a child with knowlesi malaria was 74365/μL, in an 11-year-old boy with uncomplicated disease. There were 36 (84%) children with knowlesi malaria with nonsevere anemia at presentation, comparable to children with other *Plasmodium* species infection, with no relationship to parasitemia demonstrated. The lowest hemoglobin level of 5.1 g/dL was seen in a 4-year-old child with knowlesi malaria 2 days after treatment, with 2 other children having minimum hemoglobin levels of 7.0 g/dL, all of whom had a parasite count \<1000/μL at presentation. Children with knowlesi malaria had lower neutrophil and lymphocyte counts on presentation compared to those with other *Plasmodium* species (*P* = .002). Thirty (68%) children with knowlesi malaria had thrombocytopenia (platelet count \<150 × 10^3^/μL), including 4 (9%) with a platelet count \<50 × 10^3^ cells/μL. Frequency of thrombocytopenia in children with knowlesi malaria was comparable to those with *P. vivax* but more common than with *P. falciparum* malaria (OR, 3.0 \[95% CI, 1.1--7.7\]; *P* = .026). Children with knowlesi malaria were more likely to develop mild to moderate AKI compared to those with *P. vivax* (26% vs 10%; OR, 3.1 \[95% CI, 1.1--8.7\]; *P* = .030).

Baseline Features: Adults {#s15}
-------------------------

Duration of fever for *P. knowlesi*--infected adults was comparable to both children with *P. knowlesi* and adults with malaria due to other *Plasmodium* species ([Table 2](#T2){ref-type="table"}). Adult *P. knowlesi* cases were less likely to report abdominal pain compared to children with knowlesi malaria (23% vs 43%; OR, 0.40 \[95% CI, .2--.8\]; *P* = .004; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Adults with knowlesi malaria had lower parasite counts (median, 2541/μL) than those with vivax (median, 3765/μL; *P* = .027) or falciparum (median, 9924/μL; *P* \< .001) malaria ([Table 2](#T2){ref-type="table"}). Age was positively correlated with parasitemia in *P. knowlesi* (*r*^2^ = 0.15; *P* = .002), but not *P. falciparum* or *P. vivax* infection ([Figure 2](#F2){ref-type="fig"}). Adult *P. knowlesi* cases had a lower risk of anemia at presentation compared to adults with vivax malaria (36% vs 50%, respectively; OR, 0.6 \[95% CI, .4--.9\]; *P* = .013), and children with knowlesi malaria (36% vs 82%; OR, 0.13 \[95% CI, .06--.28\]; *P* \< .001). As with children, in adult knowlesi malaria parasitemia was not associated with anemia at enrollment after controlling for age. Adults with knowlesi malaria had lower platelet counts than those with other *Plasmodium* species (*P* \< .001), with thrombocytopenia more common in adults compared to children with knowlesi malaria (92% vs 68%, respectively; *P* \< .001). The risk of AKI was higher in adult *P. knowlesi* patients compared to *P. vivax* (19% vs 10%, respectively; OR, 2.1 \[95% CI, 1.1--4.3\]; *P* = .033), although this did not remain statistically significant after controlling for age; and was also comparable to that seen in both adults with *P. falciparum* and children with knowlesi malaria. Liver aminotransferases were higher in adults with knowlesi malaria compared to those with *P. vivax* including after controlling for age (*P* = .001). Of the 322 adults with knowlesi malaria who had blood cultures, only 1 grew a noncontaminant isolate, a 14-year-old with *Neisseria meningitidis*.

###### 

Baseline Demographic, Clinical, and Laboratory Features in Adults

  Patient Characteristic                                   *Plasmodium knowlesi*   *Plasmodium vivax*   *Plasmodium falciparum*   *P* Value
  -------------------------------------------------------- ----------------------- -------------------- ------------------------- ------------------
  Adults (age \>12 y), No. (% total)                       437 (90.9)              101 (58.7)           65 (67.7)                 **\<.001**
  Age, y                                                                                                                          
   Median (IQR)                                            35 (25--50)             27 (17--35)          24 (16--47)               **\<.001**
   Range                                                   13--85                  13--70               1--12                     
  Male sex, No. (%)                                        345 (78.9)              76 (75.2)            48 (73.8)                 .522
  Previous malaria (self-reported), No. (%)                93 (21.3)               26 (25.7)            8 (12.7)                  .137
  History of chronic disease, No. (%)                      35 (8.0)                2 (2.0)              3 (4.6)                   .066
  Days of fever                                            4 (3--7)                5 (3--7)             4 (3--6)                  .089
  Symptoms on enrollment, No. (%)                                                                                                 
   Rigors                                                  359 (82.3)              86 (85.1)            49 (76.6)                 .369
   Headache                                                389 (89.0)              93 (92.1)            56 (86.2)                 .469
   Vomiting                                                105 (24.0)              43 (42.6)            28 (43.1)                 **\<.001**
   Abdominal pain                                          102 (23.3)              25 (24.8)            18 (27.7)                 .734
   Diarrhea                                                36 (8.2)                10 (9.9)             7 (10.8)                  .726
   Cough                                                   153 (35.0)              32 (31.7)            22 (33.8)                 .814
   Shortness of breath                                     70 (16.0)               20 (19.8)            10 (15.4)                 .630
   Myalgia                                                 269 (61.6)              58 (57.4)            35 (53.8)                 .418
   Arthralgia                                              289 (66.1)              59 (58.4)            34 (52.3)                 .052
  Examination findings on enrollment                                                                                              
   Temperature, °C                                         37.4 (37.0--38.1)       37.4 (36.9--38.0)    37.0 (36.8--38)           **.001**
   Fever (≥37.5°C), No. (%)                                215 (49.3)              47 (46.5)            23 (35.4)                 .634
   Systolic blood pressure, mm Hg                          120 (110--130)          115 (106--125)       112 (106--125)            **.004** ^**a**^
   Heart rate, beats/min                                   88 (77--100)            92 (78--102)         92 (81--100)              **.025** ^**a**^
   Respiratory rate, breaths/min                           20 (20--24)             20 (20--22)          21 (20--22)               .260
   Oxygen saturation, %                                    98 (97--99)             99 (98--100)         99 (98--100)              **\<.001**
   Palpable liver, No. (%)                                 105 (24.0)              21 (20.8)            11 (16.9)                 .390
   Palpable spleen, No. (%)                                26 (5.9)                9 (8.9)              6 (9.2)                   .404
   Rash, No. (%)                                           19 (4.3)                3 (3.0)              1 (1.6)                   .492
  Parasite count/μL                                        2541 (478--8585)        3765 (1755--8122)    9924 (2522--22860)        **\<.001**
  Parasite count/μL, range                                 20--263772              53--184353           33--693922                
  Schizont proportion, mean % (SD)                         2 (5.4)                 1 (2.1)              0 (0.1)                   **\<.001**
  Schizont proportion \>10%, No. (%)                       32/432 (7.4)            2/99 (2.0)           0 (0)                     **.014**
  Parasite count \>20000/μL, No. (%)                       64 (15)                 7 (7)                21 (32)                   **\<.001**
  Gametocytes present, no./No. (%)                         54/379 (14)             48/92 (52)           7/31 (23)                 **\<.001**
  Hemoglobin, g/dL                                         13.2 (12.1--14.3)       12.8 (11.2--14.2)    13.1 (11.3--14.4)         .058
  Anemia\* (baseline), No. (%)                             156 (36)                50 (50)              26 (41)                   **.041**
  G6PD deficiency present, no./No. (%)                     4/364 (1.1)             4/94 (4.3)           1/48 (2.1)                .117
  White blood cell count, × 10^3^/μL                       6.1 (5.1--7.6)          6.5 (5.3--7.8)       6.5 (5.1--8.0)            **.013**
  Neutrophil count, × 10^3^/μL                             3.5 (2.6--4.5)          4.0 (3.0--5.1)       4.2 (3.1--5.4)            **\<.001**
  Lymphocyte count, × 10^3^/μL                             1.4 (1.0--1.9)          1.4 (1.1--2.0)       1.4 (1.0--2.3)            .675
  Monocyte count, × 10^3^/μL                               1.0 (0.7--1.4)          0.7 (0.5--1.0)       0.7 (0.5--1.0)            **\<.001**
  Platelet count, × 10^3^/μL                               70 (50--103)            95 (66--134)         91 (54--149)              **\<.001**
  Platelet nadir, × 10^3^/μL                               60 (42--83)             85 (56--115)         81 (44--135)              **\<.001**
  Platelet nadir, d                                        1 (1-1)                 1 (1-1)              1 (1-1)                   1.000
  Thrombocytopenia (platelets \<150 × 10^3^/μL), No. (%)   401 (92)                82 (81)              49 (75)                   **\<.001**
  Creatinine, μmol/L                                       88 (75--103)            78 (61--93)          75 (58--91)               **\<.001**
  Urea, mmol/L                                             5.2 (3.8--6.8)          4.7 (3.5--5.8)       5.0 (3.5--7.2)            **.032**
  Sodium, mmol/L                                           136 (134--139)          137 (135--139)       136 (134--139)            .819
  Bilirubin, μmol/L                                        17.1 (11.8--24.6)       14.0 (7.6--23.0)     18.3 (10.2--30.0)         **.032**
  Glucose, mmol/L                                          6.4 (5.6--7.4)          6.3 (5.7--6.7)       6.3 (5.3--7.5)            .272
  Albumin, g/dL                                            36 (30--40)             34 (30--38)          32 (29--37)               **.011**
  AST, IU/L                                                34 (23--47)             10 (6--15)           28 (16--37)               **\<.001**
  ALT, IU/L                                                37 (24--56)             23 (14--36)          36 (22--48)               **\<.001**
  Bicarbonate, mmol/L                                      24 (21--27)             23 (21--25)          22 (20--24)               .921
  Acute kidney injury, No. (%)                             83 (19)                 10 (10)              17 (27)                   **.018**
  Blood culture positive^b^, No. (%)                       1/322 (\<1)             0/64 (0)             0/31 (0)                  1.000

Data are presented as median (IQR) unless otherwise indicated. Includes 2 *P. knowlesi* and 1 *P. falciparum* uncomplicated malaria adult patients given single-dose treatment by public health workers prior to enrollment.

P values in bold font indicate a value \<0.05.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range; SD, standard deviation.

^**\***^Anemia based on World Health Organization 2011 hemoglobin measurement criteria \[18\]: age 6--59 months (≤100 g/dL), 5--11 years (\<115 g/dL), 12--14 years (\<120 g/dL), nonpregnant women ≥15 years (\<120 g/dL), pregnant women (\<110 g/dL), men ≥15 years (\<130 g/dL).

^**a**^Comparisons did not remain statistically significant after controlling for age.

^b^Excluding results positive for skin contaminants; 1 patient with knowlesi malaria was positive for *Neisseria meningitidis.*

![Proportion of cases and median parasite count by age-group and Plasmodium spp.](ciy06502){#F2}

Severe Malaria {#s16}
--------------

*Plasmodium knowlesi* was the most common cause of severe malaria, with 28 of 481 (5.8%) knowlesi cases having severe disease ([Table 3](#T3){ref-type="table"}), all of whom were adults (28/437; 6.4% \[95% CI, 3.9%--8.3%\]. Of the severe knowlesi cases, 19 (68%) had severe malaria on presentation and 9 (32%) developed severe complications following commencement of treatment. A single severity criterion defined severe malaria in 16 (57%), with 12 (43%) patients having ≥2 criteria ([Table 4](#T4){ref-type="table"}). The most common severity criterion was severe AKI (creatinine \>265 μmol/L), occurring in 10 (35.7%) severe knowlesi patients, including a single patient who progressed to severe AKI on day 1 of admission. Eight (29%) knowlesi patients had hyperparasitemia \>100000/μL, including 5 (18%) as a sole severity criterion. Parasite counts were higher in severe knowlesi compared to nonsevere knowlesi malaria (median, 42224 vs 2044 parasites/μL, respectively; *P* \< .001). The platelet count was lower in severe vs uncomplicated knowlesi malaria (median, 56 vs 75 × 10^3^ cells/μL, respectively; *P* = .004), neutrophil count was higher (median, 4.9 vs 3.7 × 10^3^ cells/μL, respectively; *P* = .004), and proportion of patients with hyponatremia was higher (48% vs 28%, respectively; *P* = .028). Five (18%) knowlesi patients had documented hypotension, all of whom had other severity criteria including 2 patients with respiratory distress. Empiric antibiotic treatment was given to 9 (32%) patients with severe knowlesi malaria. Of the 4 severe *P. vivax* cases, 2 were children with hyperbilirubinemia and a parasite count \>20000/μL, both with moderate anemia (hemoglobin nadir of 6.8 g/dL and 9.1 g/dL, respectively). The other 2 patients with severe vivax malaria were adults, including a 17-year-old female with severe anemia, and a 53-year-old man with hypotension and respiratory distress. There were 5 patients with severe falciparum malaria (5.2%), including 2 children. No patient with malaria from any *Plasmodium* species had coma.

###### 

Severe Malaria

  Characteristic    Plasmodium knowlesi (N = 481)   *Plasmodium vivax*(N = 172)   *Plasmodium falciparum*(N = 96)   *P* Value
  ----------------- ------------------------------- ----------------------------- --------------------------------- ------------
  Severe cases                                                                                                      
   No.              28                              4                             5                                 
   %                5.8                             2.3                           5.2                               .225
   95% CI           3.9--8.3                        0.6--5.8                      1.7--11.7                         
  Age, y                                                                                                            
   Median           53                              11                            14                                **\<.001**
   IQR              43--64                          4--35                         2--16                             
   Range            13--78                          3--53                         1--26                             
  Child age ≤12 y                                                                                                   
   No.              0                               2                             2                                 **.001**
   %                0                               2.8                           6.5                               
  Male sex                                                                                                          
   No.              19                              2                             4                                 .709
   % severe         68                              50                            80                                
  Parasitemia/μL                                                                                                    
   Median           42225                           19333                         297000                            **.031**
   IQR              17221--103577                   6076--43680                   85505--635415                     

P values in bold font indicate a value \<0.05.

Abbreviations: CI, confidence interval; IQR, interquartile range.

###### 

Severe *Plasmodium knowlesi* Malaria Characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  WHO Severity Criteria                          Definition                                                                                                No.   \% Severe\   \% Total\
                                                                                                                                                                 (n = 28)     (n = 481)
  ---------------------------------------------- --------------------------------------------------------------------------------------------------------- ----- ------------ -----------
  Hyperparasitemia                               Parasite count \>100000/μL                                                                                8     28.6         1.7

  Hypotension                                    Systolic blood pressure \<70 mm Hg in children or \<80 mm Hg in adults                                    5     17.9         1.0

  Impaired consciousness                         Glasgow coma score \<11 in adults or Blantyre coma score \<3 in children                                  0     0            0

  Metabolic acidosis                             Plasma bicarbonate \<15 mmol/L                                                                            3     10.7         0.6

  Respiratory distress                           Oxygen saturation \<92% on room air with a respiratory rate \>30/min                                      2     7.1          0.4

  Jaundice                                       Total bilirubin \>50 μmol/L; with parasite count \>20000/μL and/or creatinine level \>132 μmol/L          8     28.6         2.0

  Severe acute kidney injury                     Plasma or serum creatinine \>265 μmol/L                                                                   10    35.7         2.1

  Severe malarial anemia^a^                      Hemoglobin concentration \<5 g/dL in children, and \<7 g/dL in adults                                     8     28.6         1.7

  Hypoglycemia                                   Blood or plasma glucose \<2.2 mmol/L                                                                      1     3.6          0.2

  Significant bleeding                           Including recurrent or prolonged bleeding from nose, gums, or venipuncture sites; hematemesis or melena   1     3.6          0.2

  ≥2 criteria                                                                                                                                              12    42.9         2.5

  Severe criteria developed after presentation                                                                                                             8     28.6         1.7

  Transfer to tertiary hospital                                                                                                                            15    53.6         3.1

  Admitted to ICU                                                                                                                                          10    35.7         2.1

  Death                                                                                                                                                    2     7.1          0.4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

P values in bold font indicate a value \<0.05.

Abbreviations: ICU, intensive care unit; WHO, World Health Organization.

^a^Includes 2 *Plasmodium knowlesi* patients with serious underlying medical illness: 1 with worsening of known chronic kidney disease (acute kidney injury) and another with endometriosis-associated bleeding (anemia).

Predictors of Severe Malaria {#s17}
----------------------------

On multivariate logistic regression controlling for age and parasitemia, independent clinical and parasitological predictors of severe disease in knowlesi malaria included schizont proportion \>10%, abdominal pain, and dyspnea ([Table 5](#T5){ref-type="table"}). Among WHO laboratory severity criteria, creatinine, hemoglobin, bicarbonate, and bilirubin remained independent predictors of severe disease when patients with only a single WHO severity criterion based on these measures were reclassified as nonsevere. A parasite threshold of 15000/μL had the best-combined sensitivity (74%) and specificity (87%) for predicting severe knowlesi malaria, with an area under the curve of 0.80 (95% CI, .71--.90) and a negative predictive value of 98.5%. Age ≥45 years was the best predictor of hyperparasitemia when controlling for other variables (adjusted OR, 4.9 \[95% CI, 1.0--23.9\]; *P* = .048). Adults with knowlesi malaria had a higher risk of severe disease compared to adult patients with vivax malaria (OR, 3.4 \[95% CI, .8--14.5\]; *P* = .098), and a comparable risk to falciparum malaria.

###### 

Selected Clinical and Laboratory Predictors of Severe Knowlesi Malaria at Presentation

  Variable                                UM   SM   Univariate Analysis^a^   ROC Analysis    Multivariate Analysis^b^                                                                    
  --------------------------------------- ---- ---- ------------------------ --------------- -------------------------- ---- ---- ------ ------ ------ ------------ ------ ------------- --------------
  Age \>40 y                              37   79   6.3                      (2.5--16.0)     \<.001                     79   63   11.7   98.0   0.71   (.63--.79)   5.7    (1.8--17.6)   **.003**
  Age \>45 y                              28   71   6.5                      (2.8--15.1)     \<.001                     71   72   13.7   97.6   0.72   (.63--.81)   7.3    (2.6--21.0)   **\<.001**
  Age \>50 y                              20   57   5.3                      (2.4--11.6)     \<.001                     57   80   15.0   96.8   0.69   (.59--.78)   4.5    (1.8--11.4)   **.001**
  Male sex                                23   68   1.6                      (.7--3.7)       .245                       32   78   8.1    94.9   0.55   (.46--.64)   1.7    (.6--5.0)     .312
  Previous malaria episode                19   36   2.3                      (1.0--5.2)      .039                       36   81   10.3   95.3   0.57   (.47--.66)   2.4    (.9--6.6)     .530
  Chronic disease                         6    29   5.9                      (2.4--14.4)     \<.001                     29   94   21.6   95.5   0.61   (.52--.70)   2.3    (.7--7.4)     .170
  Abdominal pain                          24   46   2.8                      (1.3--6.0)      .010                       46   76   10.7   95.8   0.61   (.52--.71)   3.5    (1.3--9.2)    **.013**
  Shortness of breath                     14   39   4.1                      (1.8--9.1)      .001                       39   86   15.1   95.8   0.63   (.54--.72)   4.1    (1.5--11.0)   **.005**
  Parasite count \>10000/μL               17   79   12.6                     (4.8--33.0)     \<.001                     74   82   21.8   98.4   0.78   (.68--.87)   10.0   (3.7--26.8)   **\<.001**
  Parasite count \>15000/μL               12   79   18.8                     (7.1--49.6)     \<.001                     74   87   28.6   98.5   0.80   (.71--.90)   16.1   (5.9--44.0)   **\<.001**
  Parasite count \>20000/μL               11   64   11.6                     (4.8--28.2)     \<.001                     61   88   26.5   97.6   0.75   (.64--.85)   8.9    (3.5--27.6)   **\<.001**
  Parasite count \>35000/μL               5    57   18.1                     (7.3--45.0)     \<.001                     52   94   42.1   97.3   0.73   (.63--.84)   12.8   (4.9--33.6)   **\<.001**
  Schizont proportion \>1%                31   57   2.9                      (1.4--6.4)      .006                       57   69   57.1   68.8   0.63   (.53--.73)   1.4    (.5--3.6)     .510
  Schizont proportion \>10%               8    18   2.7                      (1.0--7.5)      .060                       18   92   17.9   92.5   0.55   (.48--.63)   5.3    (1.5--19.4)   **.011**
  Platelets \<30 × 10^3^/μL               6    18   3.7                      (1.3--10.5)     .014                       18   94   17.9   94.4   0.56   (.49--.63)   1.4    (.4--5.0)     .623
  Platelets \<50 × 10^3^/μL               22   43   2.6                      (1.2--5.7)      .015                       43   78   10.7   95.6   0.60   (.51--.70)   1.2    (.5--3.1)     .703
  Bilirubin \>25 μmol/L                   21   50   3.3                      (1.2--8.7)      .018                       47   79   9.1    97.0   0.63   (.50--.75)   1.9    (.6--5.6)     .244
  Bilirubin \>30 μmol/L                   14   46   4.1                      (1.5--11.3)     .006                       41   86   11.3   97.0   0.63   (.51--.76)   2.3    (.7--7.0)     .147
  Bilirubin \>50 μmol/L                   3    33   10.9                     (3.4--35.2)     \<.001                     29   96   26.3   96.8   0.63   (.52--.74)   5.1    (1.4--19.4)   **.016** ^c^
  Creatinine \>100 μmol/L                 24   61   4.3                      (1.9--9.6)      \<.001                     58   76   12.3   69.8   0.67   (.57--.77)   3.1    (1.1--8.6)    **.028** ^c^
  Creatinine \>132 μmol/L                 5    28   14.9                     (6.2--35.7)     \<.001                     46   95   33.3   96.8   0.70   (.61--.80)   6.6    (2.3--19.2)   **.001** ^c^
  Creatinine \>150 μmol/L                 3    43   17.8                     (6.9--45.6)     \<.001                     38   97   40.0   96.4   0.68   (.58--.77)   6.9    (2.1--22.1)   **.001** ^c^
  Hemoglobin \<9 g/dL                     2    29   7.4                      (2.2--24.9)     .001                       17   97   25.0   95.7   0.57   (.49--.65)   13.5   (2.4--75.6)   **.003** ^c^
  Hemoglobin \<10 g/dL                    6    36   4.6                      (1.7--12.3)     .003                       25   93   16.2   95.9   0.59   (.50--.68)   8.1    (2.2--29.8)   **.002** ^c^
  Anemia (WHO age criteria)               34   64   4.1                      (1.5--11.0)     .005                       68   65   7.6    98.0   0.67   (.56--.78)   4.1    (1.4--12.5)   **.012** ^c^
  Neutrophil count \>4.0 × 10^3^/μL       34   60   2.9                      (1.3--6.5)      .013                       60   66   9.0    96.6   0.63   (.53--.73)   1.3    (.5--3.4)     .661
  Bicarbonate \<20 mmol/L                 15   38   3.4                      (1.4--8.6)      .009                       38   85   12.7   95.9   0.61   (.51--.72)   2.4    (.8--7.3)     .128
  Bicarbonate \<18 mmol/L                 1    24   22.2                     (5.8--84.5)     \<.001                     24   99   50.0   95.7   0.61   (.52--.71)   19.6   (2.9--132)    **.002** ^c^
  Age ≥45 and parasite count \>15000/μL   5    68   43.3                     (16.4--114.6)   \<.001                     65   96   44.1   98.2   0.81   (.71--.91)   ...                  
  Age ≥45 or parasite count \>15000/μL    46   89   10.6                     (3.1--36.1)     \<.001                     87   61   10.2   98.9   0.74   (.67--.82)   ...                  
  Age ≥50 or parasite count \>20000/μL    3    50   8.4                      (3.1--21.2)     \<.001                     78   70   11.6   98.5   0.74   (.65--.83)   ...                  
  Age ≥45 or chronic disease              31   79   8.0                      (3.2--20.2)     \<.001                     79   69   13.4   98.1   0.74   (.66--.82)   6.6    (2.4--17.8)   **\<.001**

All odds ratios are presented using the complement within the defined variable, for example, age \>40 years compared with ≤40 years.

P values in bold font indicate a value \<0.05.

Abbreviations: aOR, adjusted odds ratio; AUC, area under the curve; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; ROC, receiver operating characteristic; Sens, sensitivity; SM, severe malaria; Spec, specificity; UM, uncomplicated malaria; WHO, World Health Organization.

^a^Univariate analysis: patients with only a single severity criterion (hyperparasitemia, acute kidney injury, anemia, respiratory distress, acidosis, or jaundice) were considered nonsevere for the relevant analysis of the corresponding clinical or investigation result.

^b^Multivariate analysis controlled for: age and ln(parasitemia). Patients with hyperparasitemia as a single severity criterion were considered nonsevere.

^c^Creatinine, hemoglobin, bicarbonate, and bilirubin at the thresholds shown remained independent predictors of severe disease when patients with only a single WHO severity criterion based on these markers were reclassified as nonsevere.

Case Fatalities {#s18}
---------------

There were 2 deaths attributed to malaria, both *P. knowlesi*, giving an overall *P. knowlesi* case fatality risk of 2 of 481 (0.4% \[95% CI, 0.1%--1.5%\]), or 2 of 437 (0.5% \[95% CI, 0.1%--1.6%\]) in adults. The *P. knowlesi*--related deaths were a 62-year-old woman with hyperparasitemia (263772/μL) and moderate AKI (creatinine: 224 μmol/L), who developed hypotension and acute respiratory distress \[[@CIT0006]\], and a 50-year-old man presenting with severe AKI (creatinine: 609 μmol/L), parasitemia of 71939/μL, and moderate anemia (hemoglobin: 9.9 g/dL).

DISCUSSION {#s19}
==========

This study is the largest series of *P. knowlesi* malaria cases to date, and the first to prospectively compare the clinical spectrum of disease between adults and children. Although 91% of knowlesi malaria cases were adults, morbidity in children was also demonstrated, with an 11-fold higher risk of anemia at presentation and a similar risk of mild to moderate AKI compared to adults \[[@CIT0001], [@CIT0007]\]. The majority of adults with knowlesi malaria had uncomplicated disease and, compared to those with vivax and falciparum malaria, were older, with a lower risk of nonsevere anemia and a higher risk of thrombocytopenia, consistent with previous reports \[[@CIT0001], [@CIT0017], [@CIT0018]\]. The lower parasitemia in both children and adults with clinical illness from *P. knowlesi* infection compared with the human-only *Plasmodium* species may indicate a lower pyrogenic threshold and greater inflammatory response, consistent with poor adaptation of this zoonotic parasite to the human host. Although *P. knowlesi* has a 24-hour blood-stage life cycle in humans, the low parasitemia in most infections may indicate variable efficiency in human red blood cell (RBC) invasion \[[@CIT0031]\]. Only a minority had high parasitemia, with parasitemia an independent predictor of severe knowlesi malaria overall. Notably, there was no coma or convulsions seen in any patient with knowlesi malaria, consistent with previous studies \[[@CIT0006], [@CIT0017], [@CIT0018], [@CIT0032]\]. No child with knowlesi malaria had severe manifestations (although borderline severe anemia was present in one), in contrast to the severe disease found in pediatric falciparum and vivax malaria in this series and elsewhere \[[@CIT0026]\].

A lower proportion of *P. knowlesi* infections were in children compared to those with *P. vivax* or *P. falciparum*. The lower incidence of clinical disease from *P. knowlesi* infection in infants and also older children has been attributed to epidemiological factors such as lower forest exposure \[[@CIT0001], [@CIT0013], [@CIT0018]\], although contributing age-related innate protective mechanisms are plausible \[[@CIT0033]\], and asymptomatic infection has been reported in children \[[@CIT0034]\]. Most children with knowlesi malaria had anemia at enrollment, consistent with a previous retrospective report \[[@CIT0022]\]. Although adults with knowlesi malaria had higher parasite counts, nonsevere anemia was more common in children, suggesting that children may have a higher rate of uninfected RBC destruction and/or greater dyserythropoiesis, although underlying mechanisms and baseline community anemia prevalence require further investigation \[[@CIT0035]\]. Children with knowlesi malaria had lower parasitemia and platelet counts compared to children with either *P. vivax* or *P. falciparum* infection, in addition to a lower neutrophil count compared to *P. vivax*. However, there was a comparable risk of nonsevere anemia and AKI seen in *P. knowlesi*--infected children as in those with *P. vivax* or *P. falciparum*.

The proportion of adults with severe disease from *P. knowlesi* infection was comparable to that seen in *P. falciparum*. The risk of severe knowlesi malaria in this primary referral setting in Sabah, 6.2% in adults, was similar to district hospital presentations in Sarawak (9.3%) \[[@CIT0017]\], and lower than that demonstrated in a tertiary hospital setting of 29% \[[@CIT0018]\]. Severe AKI was the most frequent severity criterion, and has commonly been reported in other adult studies \[[@CIT0017], [@CIT0018], [@CIT0032]\]. Severe anemia was present in a larger proportion of adults with severe knowlesi malaria than in a previous tertiary-referral study, which reported anemia as a severe criterion in only 5% of adults, 1 of whom was splenectomized \[[@CIT0018]\]. *Plasmodium knowlesi* parasitemia \[[@CIT0018], [@CIT0032]\] and age \[[@CIT0033]\] independently predicted severe disease in this study, in addition to abdominal pain and dyspnea, which have not been previously demonstrated. Parasite counts were higher in severe knowlesi malaria than in uncomplicated disease despite no difference in the number of preceding days of fever, which suggests differences in efficacy and tropism of normocyte invasion and parasite multiplication \[[@CIT0031]\]. With age an independent risk factor for both parasitemia and severity, the immunosenescence that occurs with aging \[[@CIT0033], [@CIT0036]\] may also result in impaired control of parasite multiplication.

The pathophysiological mechanisms in severe knowlesi malaria are not well understood but likely differ from *P. falciparum*, with coma remaining unreported and a lack of the retinal microcirculatory changes found in severe falciparum malaria \[[@CIT0037]\]. With endothelial activation and systemic inflammation at least as high in response to *P. knowlesi* as in *P. falciparum* infection \[[@CIT0033], [@CIT0036]\], these processes also likely contribute to pathogenesis, particularly with the comparatively low parasite biomass able to produce severe disease observed in this study. The nature and role of microvascular accumulation of parasitized RBCs, a key mechanism of severe knowlesi malaria in rhesus macaques and also observed in a single human autopsy report \[[@CIT0021]\], requires investigation. RBC deformability is reduced in proportion to disease severity in knowlesi malaria \[[@CIT0038]\], however the role of hemolysis and endothelial dysfunction, other key pathogenic mechanisms also present in severe falciparum malaria \[[@CIT0039]\], require further investigation. Phenotypic glucose-6-phosphate dehydrogenase deficiency has been shown to protect against knowlesi malaria \[[@CIT0013]\]. Other host genetic factors related to selection pressure from historical human-only *Plasmodium* transmission may also modulate disease severity.

Current knowlesi malaria management guidelines in Sabah recommend referral for tertiary care and initial treatment with intravenous artesunate for any patients \>50 years of age or with a parasitemia \>20000/μL \[[@CIT0018], [@CIT0040]\]. Along with appropriate intravenous artesunate administration for severe malaria due to any *Plasmodium* species, these management guidelines have contributed to a decline in reported malaria case-fatality rate \[[@CIT0006], [@CIT0018], [@CIT0020]\]. In the current study, predictors were limited to severe disease given the low case-fatality rate, with a parasite threshold of 15000 parasites/μL giving a high negative predictive value of 98.5%. A conservative approach would be to recommend early administration of intravenous artesunate initially for any knowlesi malaria case with a parasite count above this threshold, given the potential delay or inability to evaluate other laboratory markers of severe disease in most primary care settings.

In conclusion, although the majority of cases are uncomplicated, *P. knowlesi* infection causes morbidity at comparatively low parasitemia in both adults and children. Adults are at risk of severe and fatal disease, in contrast to children, among whom this was not demonstrated. A conservative treatment approach utilizing parasite counts to predict severe disease is warranted.

Supplementary Data {#s20}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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